Zinpentraxin alfa is under clinical development by F. Hoffmann-La Roche and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Zinpentraxin alfa’s likelihood of approval (LoA) and phase transition for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) took place on 04 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Zinpentraxin alfa Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Zinpentraxin alfa overview

Zinpentraxin alfa (PRM-151) is under development for the treatment of idiopathic pulmonary fibrosis, myelofibrosis, fibrostenotic Crohn’s disease (FCD), post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, liver fibrosis, acute and chronic nephropathy, and age-related macular degeneration. The drug candidate is administered through intravenous, subcutaneous, subconjunctival and inhalational routes. PRM-151 is a recombinant form of human serum amyloid P which is also known as pentraxin-2. The drug candidate is based on the pentraxin-2 platform. It was also under development for the treatment of chronic kidney disease, kidney fibrosis, radiation-induced oral mucositis and cardiac fibrosis, prevention of postoperative scarring in glaucoma, chronic obstructive pulmonary disease (COPD) and asthma.

F. Hoffmann-La Roche overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

Quick View Zinpentraxin alfa LOA Data

Report Segments
  • Innovator
Drug Name
  • Zinpentraxin alfa
Administration Pathway
  • Inhalational
  • Intravenous
  • Subconjunctival
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Oncology
  • Ophthalmology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.